# Nuvalent, Inc. stock analysis

Nuvalent, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are Zidesamtinib (NVL-520), a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine ki

## Market evidence and data freshness

The public preview recorded Nuvalent, Inc. at 123.96 USD on 2026-07-14T20:00:00.000Z and marked the quote as delayed. This observation is not a trading signal.
Available price history spans 2021-09-30 through 2026-07-21 across 1205 observations; the listed source is CommonQuant Parquet archive backed by Yahoo Finance delayed data. The history end date differs from the latest quote date.

## What should I review before buying Nuvalent, Inc. stock?

Compare valuation with reported financial performance, inspect the price history, and weigh the evidence for and against the investment case. Review the risks and assumptions before making your own decision.

## Inside the full report

- Valuation
- Growth
- Financial health
- Ownership
- Research

Sign in to open the full analysis. Paid plans use included reports first, then 50 credits per additional report. Reports outside your included market also cost 50 credits. Credit access lasts 72 hours, including revisits.

[Read the report](https://commonquant.ai/markets/nuvl)